Welcome to Browse Page of Biomarker

This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.

The total number entries retrieved from this search are 594
Please click on Biomarker_ID to view detailed information.
Note: Potential Biomarker with * indicates these signatures are candidate biomarkers extracted from experiments on mice, rat or cell lines and they are not validated on human patients'cohort.
Biomarker IDBiomarkerBiomoleculeSubjectRegulationBiomarker's typeExperimentLevel of significanceSourcePMID
2201BMK, (with cut off 0.40 BMK in Urine)ProteinHumanNA DiagnosticHCC v/s Non-HCC NASerum and Urine29152526
2202AFP, BMK, (with cut off 1.25 of AFP in serum and 0.25 BMK in urine)ProteinHumanNA DiagnosticHCC v/s Non-HCC NASerum and Urine29152526
2203AFP, BMK, (with cut off 1.20 of AFP in serum and 0.27 BMK in urine)ProteinHumanNA DiagnosticHCC v/s Non-HCC NASerum and Urine29152526
2204AFP, BMK, (with cut off 0.90 of AFP in serum and 0.40 BMK in urine)ProteinHumanNA DiagnosticHCC v/s Non-HCC NASerum and Urine29152526
2205AFP, BMK, (with cut off 1.65 of AFP in serum and 0.40 BMK n urine)ProteinHumanNA DiagnosticHCC v/s Non-HCC NASerum and Urine29152526
2206AFP, BMK, (with cut off 0.9 of AFP in serum and 0.75 BMK in urine)ProteinHumanNA DiagnosticHCC v/s Non-HCC NASerum and Urine29152526
2207NLR (neutrophil to lymphocyte ratio) and SII (Systemic Immune-Inflammation Index)Neutrophils and lyphocytes (Others)HumanNLR and SII in patients associated with more advanced stages of HCC PrognosticNormal vs HCC; associated with TNM stage, PST and survival of patients p < 0.05Blood29123264
2208SULT1A3/4ProteinHumanUpregulated in HCC PrognosticHCC v/s Normal; associated with metastatsis of patients p < 0.01Tissue29025375
2209ITGA2ProteinHumanUpregulated in HCC DiagnosticHBV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.0001Tissue28947976
2210BMP4ProteinHumanUpregulated in HCC DiagnosticHBV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.0001Tissue28947976
2211PLCB1ProteinHumanUpregulated in HCC DiagnosticHBV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.0001Tissue28947976
2212KDM6BProteinHumanDownregulated in HCC DiagnosticHBV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.0001Tissue28947976
2213MYCProteinHumanDownregulated in HCC DiagnosticHBV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.0001Tissue28947976
2214ITGA2ProteinHumanUpregulated in HCC DiagnosticHCV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.01Tissue28947976
2215BMP4ProteinHumanUpregulated in HCC DiagnosticHCV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.01Tissue28947976
2216PLCB1ProteinHumanUpregulated in HCC DiagnosticHCV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.01Tissue28947976
2217KDM6BProteinHumanDownregulated in HCC DiagnosticHCV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.001Tissue28947976
2218MYCProteinHumanDownregulated in HCC DiagnosticHCV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.0001Tissue28947976
2219AFP, GGT, ALT, ASTProteinMale Sprague-Dawley ratsDownregulated Potential Prognostic *HCC v/s Normal/treated with AEA; associated with progression p < 0.0001Serum28900384
2220AFP, DCPProteinHumanAFP upregulated in HCC DiagnosticNormal vs HCC, Cirrhosis p < 0.001Serum19852963
2221DCP, (> =40 mAU/mL)ProteinHumanDCP upregulated in HCC DiagnosticNormal vs HCC, Cirrhosis p < 0.001Serum19852963
2222DCP, (> =150 mAU/mL)ProteinHumanDCP upregulated in HCC DiagnosticNormal vs HCC, Cirrhosis p < 0.001Serum19852963
2223AFP, (> =20 ng/mL)ProteinHumanAFP and DCP upregulated in HCC DiagnosticNormal vs HCC, Cirrhosis p < 0.001Serum19852963
2224AFP, (> =200 ng/mL)ProteinHumanAFP and DCP upregulated in HCC DiagnosticNormal vs HCC, Cirrhosis p < 0.001Serum19852963
2225AFP, DCP, ( DCP with a cut-off value of 86 mAU/mL and AFP with a cut-off value of 21 ng/mL)ProteinHumanAFP and DCP upregulated in HCC DiagnosticHCC v/s Normal p < 0.001Serum25382443
2226AFP, (cut-off value of 21 ng/mL)ProteinHumanAFP upregulated in HCC DiagnosticHCC v/s Normal p < 0.001Serum25382443
2227DCP, (cut-off value of 86 mAU/mL)ProteinHumanDCP upregulated in HCC DiagnosticHCC v/s Normal p < 0.001Serum25382443
2228AFPProteinHumanAFP upregulated in HCC DiagnosticHCC v/s Non-HCC p < 0.001Serum29163838
2229DCPProteinHumanDCP upregulated in HCC DiagnosticHCC v/s Non-HCC p < 0.001Serum29163838
2230AFP, DCP, (DCP >40 mAU/mL, AFP >20 ng/mL)ProteinHumanAFP and DCP upregulated in HCC DiagnosticHCC v/s Non-HCC p < 0.001Serum29163838
2231TP73-AS1LncRNAHumanUpregulated in HCC (with more than 2 fold change) Diagnostic and PrognosticHCC v/s Normal; associated with worse clinicopathological features, poorer prognosis and shorter survival p < 0.001Tissue28403886
2232CCAT2LncRNAHumanUpregulated in HCC DiagnosticHCC v/s Normal p < 0.05Tissue27347113
2233UCA1LncRNAHumanUpregulated in HCC DiagnosticHCC v/s Normal p < 0.05Tissue28271214
2234CCAT2LncRNAHumanUpregulated in HCC PrognosticHCC v/s Normal; associated with poor survival in HCC patients p < 0.01Tissue28280353
2235SNHG20LncRNAHumanUpregulated in HCC PrognosticHCC v/s Normal; associated with survival of patients p < 0.001Tissue27053960
2236MALAT1LncRNAHuman, Mice and cell linesUpregulated in HCC with Fold change=3.233 DiagnosticHCC v/s Normal p < 0.05Tissue27993818
2237ANRILLncRNAHumanUpregulated in HCC with Fold change >1.0 DiagnosticHCC v/s Normal p < 0.01Tissue25966845
2238CCAT1LncRNAHumanUpregulated in HCC PrognosticHCC v/s Normal; correlated with tumor size, microvascular invasion and poor prognosis p < 0.001Tissue25884472
2239lncCAMTA1LncRNAHumanUpregulated in HCC and lncCAMTA1 is increased in HCC and indicates poor outcome. PrognosticHCC v/s Normal; associated with poor recurrence free survival and overall survival of patients p < 0.01Tissue27669232
2240lncRNA-hPVT1LncRNAHumanUpregulated in HCC and higher hPVT1 expression levels in HCC tissues significantly correlated with markedly reduced recurrence-free survival Diagnostic and PrognosticHCC v/s Normal; associated with recurrence and survival in patients p < 0.001Tissue25043274
2241DANCRLncRNAHumanUpregulated in HCC Diagnostic and PrognosticHCC v/s Normal/Cirrhosis/CHB;associated with metastasis of patients p < 0.001Plasma27919960
2242RP11-160H22.5LncRNAHumanUpregulated in HCC with Fold change >2.0 DiagnosticHCC v/s Normal p < 0.01Plasma25714016
2243XLOC_014172LncRNAHumanUpregulated in HCC with Fold change >2.1 Diagnostic and PrognosticHCC v/s Normal; associated with metastatsis of patients p < 0.01Plasma25714016
2244LOC149086LncRNAHumanUpregulated in HCC with Fold change >2.0 Diagnostic and PrognosticHCC v/s Normal; associated with metastatsis of patients p < 0.01Plasma25714016
2245RP11-160H22.5, XLOC_014172, LOC149086LncRNAHumanUpregulated in HCC with Fold change >2.0 Diagnostic and PrognosticHCC v/s Normal; associated with metastatsis of patients p < 0.01Plasma25714016
2246HLA-CRNAsHumanUpregulated in HCC and CHC v/s normal (with 67 fold change) DiagnosticHCC and CHC v/s normal p < 0.01Tissue11401510
2247B2MRNAsHumanUpregulated in HCC and CHC v/s normal (with 67 fold change) DiagnosticHCC and CHC v/s normal p < 0.01Tissue11401510
2248BR1RNAsHumanUpregulated in HCC and CHC v/s normal (with 19 fold change) DiagnosticHCC v/s CHC and normal p < 0.01Tissue11401510
2249GPC3RNAsHumanUpregulated in HCC than CHC and normal (with nearly 15 fold change) DiagnosticHCC v/s CHC and normal p < 0.01Tissue11401510
2250UBDRNAsHumanUpregulated in HCC than CHC and normal (with nearly 12 fold change) DiagnosticHCC v/s CHC and normal p < 0.01Tissue11401510

         Raghava's group    CancerCSP    CancerSPP    CancerPDF    CancerTSP    CancerLSP    HCCPred   

Scroll to Top